U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16F3N3O4
Molecular Weight 371.3111
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 5-[[trans-4-[4-(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid

SMILES

OC(=O)C1=C(NN=N1)O[C@H]2CC[C@@H](CC2)C3=CC=C(OC(F)(F)F)C=C3

InChI

InChIKey=UINBFJPVDKLYIY-HOMQSWHASA-N
InChI=1S/C16H16F3N3O4/c17-16(18,19)26-12-7-3-10(4-8-12)9-1-5-11(6-2-9)25-14-13(15(23)24)20-22-21-14/h3-4,7-9,11H,1-2,5-6H2,(H,23,24)(H,20,21,22)/t9-,11-

HIDE SMILES / InChI

Molecular Formula C16H16F3N3O4
Molecular Weight 371.3111
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 17:40:57 GMT 2023
Edited
by admin
on Sat Dec 16 17:40:57 GMT 2023
Record UNII
WC82E7HRU5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
5-[[trans-4-[4-(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid
Systematic Name English
BMN255
Code English
BMN-255
Code English
1H-1,2,3-TRIAZOLE-4-CARBOXYLIC ACID, 5-((TRANS-4-(4-(TRIFLUOROMETHOXY)PHENYL)CYCLOHEXYL)OXY)-
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 882922
Created by admin on Sat Dec 16 17:40:57 GMT 2023 , Edited by admin on Sat Dec 16 17:40:57 GMT 2023
Code System Code Type Description
CAS
2360927-98-4
Created by admin on Sat Dec 16 17:40:57 GMT 2023 , Edited by admin on Sat Dec 16 17:40:57 GMT 2023
PRIMARY
FDA UNII
WC82E7HRU5
Created by admin on Sat Dec 16 17:40:57 GMT 2023 , Edited by admin on Sat Dec 16 17:40:57 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
BMN 255 (also referred to as B209859, BMN255-DS, BMN255, and BMN-255) is an oral, small molecule inhibitor of glycolate oxidase (GO) which will reduce the conversion of glycolate to glyoxylate, the metabolic precursor of oxalate, and thereby decrease urine oxalate excretion. Glycolate oxidase inhibition will also increase plasma glycolate, which is safely excreted in urine